Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP2 | O75604 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | GFER | P55789 | 1/20 | 0.33 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.32 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.32 |
| ▸ | PTGDR | Q13258 | 1/20 | 0.30 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3342629 | 1.00 | USP2 (0.35) | USP2LMNAALOX15GAAGFER | |
| SCHEMBL3343017 | 0.74 | GAA (0.40) | LMNAGAA | |
| SCHEMBL3343021 | 0.74 | GAA (0.40) | LMNAGAA | |
| SCHEMBL3342637 | 0.72 | HPGD (0.33) | GABRA1GABRB2PTGDRPTGDR2 | |
| SCHEMBL1739395 | 0.71 | GABRA1 (0.35) | LMNAGAAGFERGABRA1GABRB2 | |
| SCHEMBL1739396 | 0.71 | GABRA1 (0.35) | LMNAGAAGFERGABRA1GABRB2 | |
| SCHEMBL11766536 | 0.70 | GABRA1 (0.40) | ALOX15GAAGABRA1GABRB2PTGDR | |
| SCHEMBL3843623 | 0.70 | GABRA1 (0.52) | LMNAALOX15GAAGABRA1GABRB2 | |
| SCHEMBL4633136 | 0.69 | GABRA1 (0.36) | GAAGABRA1GABRB2PTGDRPTGDR2 | |
| SCHEMBL3340572 | 0.67 | ALDH1A1 (0.49) | USP2LMNAALOX15GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100160369-A1 | S1P1 Agonists and Methods of Making And Using | EXELIXIS, INC. (US) | 2010-06-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100160369-A1 | S1P1 Agonists and Methods of Making And Using | S1PR1, S1PR5, S1PR3 | USP2 4457/4885LMNA 2187/4885ALOX15 293/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.